GlassScriptPhysician profile
Joo Jung
NPI 1003518408
$2,123.63
in general payments reported to CMS, 2019-2025
13 companies · $1,589 in 2025
The $1,589 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $535 · 2025: $1,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.65 |
| Education | $295.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $377.53 | 2024-2025 | |
| Janssen Biotech, INC. | $304.72 | 2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $277.49 | 2025 | Tremfya |
| Lilly USA, LLC | $244.96 | 2024-2025 | Ebglyss, Zepbound, Taltz |
| Amgen INC. | $166.44 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $155.16 | 2024-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $149.11 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $106.51 | 2025 | |
| Sanofi-Aventis U.S. LLC | $96.99 | 2025 | |
| Pfizer INC. | $95.85 | 2025 | |
| Arcutis Biotherapeutics, INC. | $83.90 | 2025 | Zoryve |
| Almirall LLC | $40.57 | 2025 | Klisyri |
| Ucb, INC. | $24.40 | 2024 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joo Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.